Zomepirac

DB04828ApprovedWithdrawnSmall molecule

Zomepirac, formerly marketed as Zomax tablets, was associated with fatal and near-fatal anaphylactoid reactions. The manufacturer voluntarily removed Zomax tablets from the Canadian, US, and UK markets in March 1983.

Chemical structure of Zomepirac
Primary indication
Zomepirac was indicated for the management of mild to severe pain.Curator reviewed
Formula / weight
C15H14ClNO3 · 291.73 g/mol (avg)

Resolves to

Compound
UNII822G987U9JCAS33369-31-2ChEMBLCHEMBL19490ChEBI35859PubChem5733
Clinical / RWD
RxNorm39994ATCM01AB04PharmGKBPA166049188
Structure
InChIKeyZXVNMYWKKDOREA-UHFFFAOYSA-NSMILESCN1C(CC(O)=O)=CC(C)=C1C(=O)C1=CC=C(Cl)C=C1
Targets
P35354PTGS2P23219PTGS1Q9Y5Y4PTGDR2

What you can answer from here — as of September 23, 2026

3Protein targetsEach mapped to UniProt, with action and pharmacological action
Listed above
1,462Drug interactionsStructured to mechanism, not free text
Sign in
1ATC codeIncluding every combination product, plus 18 drug categories
Sign in
12+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Zomepirac, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In